亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

廣州艾格生物科技有限公司  

新藥轉(zhuǎn)讓、醫(yī)藥中間體、技術(shù)外包

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:于江月
  • 電話:86-20-28069315
  • 郵件:eggbio@163.com
  • 傳真:020-28069316
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁(yè) > 供應(yīng)產(chǎn)品 > 阿瑞匹坦中間體1
阿瑞匹坦中間體1
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 廣東廣州市付款后3天內(nèi)
型號(hào) 380499-07-0
規(guī)格 克級(jí)/百克級(jí)/千克級(jí)分別包裝
過期 長(zhǎng)期有效
更新 2013-06-06 11:05
 
詳細(xì)信息

阿瑞匹坦中間體1
       
CAS: 380499-07-0
中文名:(2R)-2-[(1R)-1-[3,5-(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)-5,6-雙氫-2H-1,4-噁嗪
英文名:(2R)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluoroph enyl)-5,6-dihydro-2H-1,4-oxazine
純度:≧99%   
包裝規(guī)格:克級(jí)/百克級(jí)/千克級(jí)分別包裝
©2025 廣州艾格生物科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:4378  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |